CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Betaxolol

· ingredient betaxololBeta blocking agents· BETAXOLOL HYDROCHLORIDE 10 mg/1; BETAXOLOL HYDROCHLORIDE 20 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.58943
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 7 weeks.

2025-11-192026-05-20

Same-ingredient options by acquisition cost

Other betaxolol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Betaxolol Hydrochloride$8.73+$8.14

Medicare Part D coverage · CY2026

On 208 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.